Lerdelimumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 2 |
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 285985-06-0  |
| ATC code | none |
 (what is this?) (verify) |
|
Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results.[2]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Pages with reference errors
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
